云南省降尿酸药品临床综合评价与遴选标准专家共识

Expert Consensus on Clinical Comprehensive Evaluation and Selection Criteria for Uric Acid-Lowering Drugs in Yunnan Province

关键词:  降尿酸药品  临床综合评价  专家共识

Key words:  Uric Acid-Lowering Drugs  Clinical Comprehensive Evaluation  Expert Consensus

摘要:

目的 开展降尿酸药品的临床综合评价，为云南省医疗机构降尿酸药物的合理使用提供参考依据。方法：依据权威指南及药品说明书等相关资料，并运用德尔菲专家咨询法，建立云南省降尿酸药品临床综合评价与遴选标准，并运用此评分标准对7种降尿酸药物进行评分。结果：该共识从有效性、安全性、经济性、适宜性、可及性以及创新性6个维度进行量化评分。总分由高到低依次为非布司他（瑞扬）、非布司他（菲布力）、别嘌醇（久联）、别嘌醇缓释胶囊（奥迈必利）、苯溴马隆（立加利仙）、苯溴马隆（尔同舒）、丙磺舒。结论：本研究以临床价值为导向，构建了一套科学规范的《云南省降尿酸药品临床综合评价与遴选标准专家共识》，为云南省医疗机构药品配备和采购目录的制定，以及药品合理使用提供科学依据。

Abstract:

OBJECTIVE To conduct the comprehensive clinical evaluation of uric acid-lowering drugs, and to provide a reference basis for the rational use of uric acid-lowering drugs in medical institutions in Yunnan Province. Methods According to authoritative guidelines and drug instructions, the Delphi expert consultation method was subjected to seek expert opinions and establish an expert consensus on the evaluation and selection scoring criteria of uric acid-lowering drugs in Yunnan Province, and used this scoring criteria to score seven uric acid-lowering drugs. Results The expert consensus adopted the percentage system for quantitative evaluation, including effectiveness, safety, economy, suitability, accessibility, and innovation. The total scores from high to low were febuxostat (Ruiyang), febuxostat (Feburic), allopurinol (Juilian), allopurinol sustained-release capsule (Aomaibili), benzylbromarone (Narcaricin), benzylbromarone (Ertongshu), and probenecid. CONCLUSION Guided by clinical value, a scientific and standardized evaluation and selection criteria of Expert Consensus on Clinical Comprehensive Evaluation and Selection Criteria for Uric Acid-Lowering Drugs in Yunnan Province is established. This study provides a scientific basis for the formulation of the medical structure drug allocation in Yunnan Province and procurement catalogue, and the rational use of drugs.